New combined antiretroviral therapy drugs have significantly improved the treatment experience for people living with HIV,with a particular focus on long-acting drugs in recent years.Capsid inhibitors represent a new class of drugs with a unique mechanism of action,of which Lenacapavir(LEN)is a key example.LEN has demonstrated remarkable efficacy in a variety of patient populations,including treatment-naive patients,patients switching therapy while virologically suppressed,and patients with multidrug-resistant HIV.In HIV pre-exposure prophylaxis(PrEP),LEN shows exceptionally high protection,offering 100％prevention of HIV infection.This article reviews the latest data on LEN,including its mechanism of action,pharmacokinetics,related studies,resistance characteristics and patient-reported outcomes,and explores its future prospects.
维普
万方数据